Walid Abi‐Saab

Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction

Deepak Cyril D’Souza, Walid Abi‐Saab, Steven Madonick et al. · Biological Psychiatry · 2005 · 604 citations

Cannabis Use, Delta-9-tetrahydrocannabinol Effects, Substance Abuse +14

Comparative and Interactive Human Psychopharmacologic Effects of Ketamine and Amphetamine

John H. Krystal, Edward Perry, Ralitza Gueorguieva et al. · Archives of General Psychiatry · 2005 · 322 citations

Extracellular metabolites in the cortex and hippocampus of epileptic patients

Idil Çavuş, Willard S. Kasoff, Michael P. Cassaday et al. · Annals of Neurology · 2005 · 287 citations

Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects

John H. Krystal, Walid Abi‐Saab, Edward Perry et al. · Psychopharmacology · 2004 · 272 citations

Psychiatry, Brain Function, Medicine +11

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial

Désirée van der Heijde, Xenofon Baraliakos, Lianne S. Gensler et al. · The Lancet · 2018 · 251 citations · Full text

Rheumatoid Disorder, Rheumatology, Autoimmune Disease +7